We're excited to share a major milestone: Omic's AI platform has successfully identified novel drug targets that have been validated through experimental studies.

## The Challenge of Target Discovery

Finding the right drug target is perhaps the most critical—and most difficult—step in drug discovery. A good target must be:

- **Disease-relevant**: Causally involved in the disease process
- **Druggable**: Amenable to modulation by small molecules or biologics
- **Safe**: Not essential for normal physiological function

Traditional target discovery relies heavily on academic literature and serendipity. Our approach uses AI to systematically analyze multi-omics data and identify targets that meet all three criteria.

## How Our AI Works

Our target discovery pipeline integrates:

1. **Transcriptomic analysis** of disease vs. healthy tissues to identify differentially expressed genes
2. **Genomic analysis** of disease-associated variants and their functional impact
3. **Protein interaction networks** to understand how potential targets connect to disease pathways
4. **Druggability assessment** using structural and chemical features

The AI then synthesizes these signals to rank potential targets by confidence and therapeutic potential.

## Validation Results

In collaboration with academic partners, we tested our AI's top predictions against experimental validation:

- **12 novel targets identified** across oncology and metabolic disease
- **8 targets validated** (67% hit rate) in cell-based assays
- **3 targets showing** drug-like small molecule binding

For context, traditional high-throughput screening campaigns typically achieve hit rates of 0.1-1%. Our AI-driven approach represents a 50-100x improvement in efficiency.

## What This Means

These results validate our core thesis: AI trained on comprehensive biological data can identify drug targets that would be missed by traditional approaches.

More importantly, this isn't just about finding targets faster—it's about finding _better_ targets. Several of our validated hits represent novel biology that wasn't previously connected to the diseases in question.

## Next Steps

With target discovery validated, we're now building out the next stages of our platform:

- **Lead discovery**: AI-driven identification of small molecules that modulate our targets
- **Digital patient models**: Computational representations of patient biology for virtual testing
- **Pipeline programs**: Internal drug discovery programs built on our validated targets

We're moving from proving the technology works to using it to discover real medicines.

* * *

_Research conducted in collaboration with academic partners. Detailed results to be published in peer-reviewed journals._

Omic - Building Biological Superintelligence to End Disease